MDT Filing
4Filing Date: Aug 4, 2026

Medtronic plc (MDT) · Insider Trading (Form 4) SEC Filing

Statement of Changes in Beneficial Ownership

descriptionView SEC Filing
ACC: 0002137804-26-000004open_in_new
Total Value$148.5K
Trades4
Insiders1

Transaction Details

Thompson Kweli
EVP & President, Neuroscience·Direct
Grant · Acquire
Stock Option (Right to Buy)Derivative
Shares+49.17K
Price$0.00
Total Value$0
Shares Owned After49.17K
Transaction DateAug 3, 2026
ExpiresAug 3, 2036
Footnotes ▸

These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.

Thompson Kweli
EVP & President, Neuroscience·Direct
Grant · Acquire
Performance Share UnitsDerivative
Shares+17.31K
Price$0.00
Total Value$0
Shares Owned After17.31K
Transaction DateAug 3, 2026
Footnotes ▸

Each performance share unit represents a contingent right to receive one share of Medtronic common stock. | Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. | Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. | The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,306 shares will be issued. If maximum performance metrics are achieved, 41,534 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

Thompson Kweli
EVP & President, Neuroscience·Direct
Grant · Acquire
Ordinary Shares
Shares+6.92K
Price$0.00
Total Value$0
Shares Owned After35.39K
Transaction DateAug 3, 2026
Footnotes ▸

Represents restricted stock units that vest 100% on the third anniversary of the date of grant.

Thompson Kweli
EVP & President, Neuroscience·Direct
Tax W/H · Dispose
Ordinary Shares
Shares-1.74K
Price$85.39
Total Value$148.5K
Shares Owned After28.47K
Transaction DateJul 31, 2026
Footnotes ▸

Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. | Includes 188 shares acquired through dividend reinvestment since the last report filed by the reporting person.

Post-Transaction Holdings

Thompson Kweli
SecuritySharesChange
Ordinary Shares35.39K+5.18K (17.16%)
Performance Share Units17.31K+17.31K
Stock Option (Right to Buy)49.17K+49.17K
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-07-31 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Medtronic plc (MDT) CIK: 0001613103 --- Reporting Owner --- Name: Thompson Kweli CIK: 0002137804 Role: Officer (EVP & President, Neuroscience) --- Non-Derivative Transactions --- [Transaction #1] Security: Ordinary Shares Date: 2026-07-31 | Code: F (Payment of exercise/tax) Shares: -1,739 | Price: $85.39 Total Value: $148,493.21 Shares Owned After: 28,467 | Ownership: D (Direct) Footnotes: [F1] Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. [F2] Includes 188 shares acquired through dividend reinvestment since the last report filed by the reporting person. [Transaction #2] Security: Ordinary Shares Date: 2026-08-03 | Code: A (Grant or award) Shares: +6,923 | Price: $0.00 Shares Owned After: 35,390 | Ownership: D (Direct) Footnotes: [F3] Represents restricted stock units that vest 100% on the third anniversary of the date of grant. --- Derivative Transactions --- [Transaction #1] Security: Performance Share Units Date: 2026-08-03 | Code: A (Grant or award) Shares: +17,306 | Price: $0.00 Shares Owned After: 17,306 | Ownership: D (Direct) Footnotes: [F4] Each performance share unit represents a contingent right to receive one share of Medtronic common stock. [F5] Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. [F5] Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. [F6] The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,306 shares will be issued. If maximum performance metrics are achieved, 41,534 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. [Transaction #2] Security: Stock Option (Right to Buy) Date: 2026-08-03 | Code: A (Grant or award) Shares: +49,167 | Price: $0.00 Exercisable: N/A | Expires: 2036-08-03 Shares Owned After: 49,167 | Ownership: D (Direct) Footnotes: [F7] These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. --- Footnotes (Complete Index) --- F1: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. F2: Includes 188 shares acquired through dividend reinvestment since the last report filed by the reporting person. F3: Represents restricted stock units that vest 100% on the third anniversary of the date of grant. F4: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5: Represents performance share units for which certain performance conditions will have been satisfied on April 27, 2029. F6: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 17,306 shares will be issued. If maximum performance metrics are achieved, 41,534 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F7: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. --- Signature --- /s/ /s/ Patricia Walesiewicz, attorney-in-fact (2026-08-04)

keid analysis is for reference only and does not constitute investment advice.